Evidence map›Paper›PMID 22326918›Full record

ArticleBiochemical and biophysical research communications2012

TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor.

Sarah Bruneau, Dipak Datta, Jesse A Flaxenburg, Soumitro Pal, David M Briscoe

Open access · greenAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. The relationship between TRAF6 and tumors.Cancer cell international · 2020
    Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Up-regulated tumor necrosis factor-associated factor 6 level is correlated with apoptosis in the rat cerebral ischemia and reperfusion.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah BruneauTransplantation Research Center, Division of Nephrology, Department of Medicine, Children's Hospital Boston, Boston, MA 02115, United States.
Dipak Datta
Jesse A Flaxenburg
Soumitro Pal
David M Briscoe
Boston Children's Hospital · USHarvard University · US

Funding

RESEARCH TRAINING IN PEDIATRIC NEPHROLOGYT32DK007726 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI BRISCOE, DAVID M. · 1994 to 2023
$5.9M
ANGIOGENESIS AND CHRONIC REJECTIONR01AI046756 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI BRISCOE, DAVID M. · 2000 to 2010
$4.2M
NIAID NIH HHS AI046756NIAID NIH HHS R01 AI046756NIDDK NIH HHS T32 DK007726
6 · The paper itself

Abstract

TNF-family molecules induce the expression Vascular Endothelial Growth Factor (VEGF) in endothelial cells (EC) and elicit signaling responses that result in angiogenesis. However, the role of TNF-receptor associated factors (TRAFs) as upstream regulators of VEGF expression or as mediators of angiogenesis is not known. In this study, HUVEC were cotransfected with a full-length VEGF promoter-luciferase construct and siRNAs to TRAF 1, -2, -3, -5, -6, and promoter activity was measured. Paradoxically, rather than inhibiting VEGF expression, we found that knockdown of TRAF6 resulted in a 4-6-fold increase in basal VEGF promoter activity compared to control siRNA-transfected EC (P<0.0001). In addition, knockdown of TRAF 1, -2, -3 or -5 resulted in a slight increase or no change in VEGF promoter activation. Using [(3)H]thymidine incorporation assays as well as the in vitro wound healing assay, we also found that basal rates of EC proliferation and migration were increased following TRAF6 knockdown; and this response was inhibited by the addition of a blocking anti-VEGF antibody into cell cultures. Using a limited protein array to gain insight into TRAF6-dependent intermediary signaling responses, we observed that TRAF6 knockdown resulted in an increase in the activity of Src family kinases. In addition, we found that treatment with AZD-0530, a pharmacological Src inhibitor, reduced the regulatory effect of TRAF6 knockdown on VEGF promoter activity. Collectively, these findings define a novel pro-angiogenic signaling response in EC that is regulated by TRAF6.

Indexed as

Transcriptional ActivationBenzodioxolesCell MovementCell ProliferationGene Knockdown TechniquesHumansHuman Umbilical Vein Endothelial CellsLuciferasesNeovascularization, PhysiologicPromoter Regions, GeneticQuinazolinesRNA, Small Interferingsrc-Family KinasesTNF Receptor-Associated Factor 6Vascular Endothelial Growth Factor ABenzodioxolesLuciferasesQuinazolinesRNA, Small Interferingsaracatinibsrc-Family KinasesTNF Receptor-Associated Factor 6Vascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID22326918
PMCPMC3285392
OpenAlexW2079090403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.